Funding for this research was provided by:
Eli Lilly and Company (Grant number H3E-US-X043)
Text and Data Mining valid from 2019-01-14
Received: 13 July 2018
Accepted: 7 January 2019
First Online: 14 January 2019
Ethics approval and consent to participate
: This study was approved under the University of Washington/Seattle Cancer Care Alliance Ethics board. All patients gave written informed consent prior to enrolling in this trial.
: Not applicable, no individual data/images presented.
: We wish to draw the attention of the Editor to the following facts which may be considered as potential conflict of interest:OrderedList removedThe remainder of the authors confirm that they have no known conflicts of interest associated with this publication and there has been no significant financial support aside from what is listed above and in the acknowledgements section that could have influenced its outcome.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.